Therapy News and Research

RSS

Data shows cost-effectiveness of ZOLL LifeVest Wearable Defibrillator

ZOLL Medical Corporation, a manufacturer of medical devices and related software solutions, announced today that data showing the cost-effectiveness of the LifeVest Wearable Defibrillator was presented in two scientific presentations and posters at the American Heart Association's Scientific Sessions 2011 in Orlando over the weekend.

14 Nov 2011

Positive results from Oncolytics REOLYSIN combination Phase 2 clinical trial for head and neck cancers

Oncolytics Biotech Inc. today announced that positive results from a Phase 2 clinical trial (REO 015) using intravenous administration of REOLYSIN in combination with paclitaxel and carboplatin in patients with advanced head and neck cancers will be presented at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics.

14 Nov 2011

BioVentrix announces completion of enrollment in PliCath HF human clinical trial

BioVentrix, developer of the PliCath HF System, today announced the achievement of a significant milestone - completion of enrollment in its pilot human clinical trial. PliCath HF is a novel device which enables Epicardial Catheter-based Ventricular Restoration (ECVR).

14 Nov 2011

Luminescent upconversion nanocrystals can detect cancer cells

Upconversion emission materials are ideal for bioimaging due to its effectiveness as contrast agents for the detection of cancer cells, more so when the background emission of non-cancerous tissues can be minimised. These materials could be used as biomarkers for luminescent labeling of cancerous cells. Opaque tissues can be turned into glassy, transparent substances by using these biomarkers which rely on near-infrared excitation.

14 Nov 2011

Scientists discover molecular basis for tamoxifen resistance and potential way to defeat it

In the last three decades, thousands of women with breast cancer have taken the drug tamoxifen, only to discover that the therapy doesn't work, either because their tumors do not respond to the treatment at all, or because they develop resistance to it over time. Now researchers at the University of California, San Francisco (UCSF) have discovered the molecular basis for tamoxifen resistance and found a potential way to defeat it.

14 Nov 2011

Scientists identify factors that lead to concomitant tumor resistance

Scientists are another step closer to understanding what drives tumor metastasis, as laboratory models suggest there are factors inside tumors that can slow their own growth.

14 Nov 2011

Genzyme's alemtuzumab Phase lll trial on MS meets co-primary endpoints

Genzyme, a Sanofi company, reports today that the Phase lll CARE-MS ll trial met both of its co-primary endpoints. Relapse rate and sustained accumulation (worsening) of disability (SAD) were significantly reduced in multiple sclerosis patients receiving alemtuzumab as compared with Rebif.

14 Nov 2011

ZIOPHARM announces darinaparsin preclinical data on prostate cancer

ZIOPHARM Oncology, Inc., a drug development company employing small molecule and synthetic biology approaches to cancer therapy, announced today that results from preclinical studies of darinaparsin (Zinapar or ZIO-101), a novel organic arsenic, in prostate cancer were presented at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, taking place November 12-16 in San Francisco.

14 Nov 2011

Combination of REGN910 and aflibercept inhibits tumor angiogenesis in animal models

Combining the investigational agents REGN910 and aflibercept yielded statistically significant improvements in antitumor effects in animal models compared with either agent alone, according to results presented at the AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics, held Nov. 12-16, 2011.

14 Nov 2011

Researchers show how ER-positive breast cancer tumors become resistant to tamoxifen

Researchers have shown how estrogen receptor-positive breast cancer tumors become resistant to tamoxifen, the only approved hormonal therapy for premenopausal patients with this type of breast cancer.

14 Nov 2011

Exelixis reports cabozantinib phase 2 trial data on bone metastases

Exelixis, Inc. today reported interim data on pain relief and related reduction in narcotic analgesic use with cabozantinib in castration-resistant prostate cancer (CRPC) patients with bone metastases.

14 Nov 2011

UCLA School of Nursing faculty members to present at AHA 2011

A failing heart's effect on the short-term memory. The impact of telephone interventions on behaviors in Latinos. Depression and heart disease. Risk factors contributing to premature coronary atherosclerosis in premenopausal women. These are just a few of the research findings that will be presented by faculty members of the UCLA School of Nursing at the American Heart Association's Scientific Sessions, being held November 12 - 16 in Orlando, FL.

14 Nov 2011

Patients with KRAS mutant NSCLC should respond well to antifolates

Patients with non-small cell lung cancer who have mutations in the KRAS gene should respond well to the antifolate class of drugs, according to results of a recent study conducted by Quintiles comparing human lung cancer cell lines and patients.

14 Nov 2011

Intensive therapy can preserve kidney function in patients with type 1 diabetes

People with type 1 diabetes are at high risk of developing kidney disease, but no therapies are proven to prevent impaired kidney function in these patients. In the Diabetes Control and Complications Trial (DCCT), Ian de Boer, MD and his team looked to see if intensive diabetes therapy aimed at reducing blood sugar as close to the normal range as possible might protect type 1 diabetics' kidney function. The study's results were presented during the American Society of Nephrology's Annual Kidney Week.

14 Nov 2011

Renowned cardiologist wins TCT 2011 Geoffrey O. Hartzler Master Clinical Operator Award

Horst Sievert, MD, PhD, a renowned interventional cardiologist, was presented the TCT 2011 Geoffrey O. Hartzler Master Clinical Operator Award in a ceremony held today during the 23rd annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium, sponsored by the Cardiovascular Research Foundation.

14 Nov 2011

Therapy News and Research

Data shows cost-effectiveness of ZOLL LifeVest Wearable Defibrillator

Positive results from Oncolytics REOLYSIN combination Phase 2 clinical trial for head and neck cancers

BioVentrix announces completion of enrollment in PliCath HF human clinical trial

Luminescent upconversion nanocrystals can detect cancer cells

Scientists discover molecular basis for tamoxifen resistance and potential way to defeat it

Scientists identify factors that lead to concomitant tumor resistance

Genzyme's alemtuzumab Phase lll trial on MS meets co-primary endpoints

ZIOPHARM announces darinaparsin preclinical data on prostate cancer

Combination of REGN910 and aflibercept inhibits tumor angiogenesis in animal models

Researchers show how ER-positive breast cancer tumors become resistant to tamoxifen

Exelixis reports cabozantinib phase 2 trial data on bone metastases

UCLA School of Nursing faculty members to present at AHA 2011

Patients with KRAS mutant NSCLC should respond well to antifolates

Intensive therapy can preserve kidney function in patients with type 1 diabetes

Renowned cardiologist wins TCT 2011 Geoffrey O. Hartzler Master Clinical Operator Award

Maintaining normal blood glucose levels prevents long-term kidney complications

Wearable defibrillator effective in preventing sudden death in people with arrhythmias

Brazilian Ministry of Health, Bristol-Myers Squibb sign technology transfer agreement for Reyataz

Parkinson’s disease breakthrough using stem cell therapy

NeoStem third quarter revenues increase to $17.8 million

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Advancing Intracellular Delivery with LumiPore®

Latest News